Pregnancy outcome following first trimester exposure to sumatriptan

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Teratology

Background:

• Sumatriptan is a medication used for migraine headaches.
• Data on the safety of sumatriptan use during pregnancy is limited.
• Assessing potential teratogenic effects is crucial for pregnant individuals.

Purpose of the Study:

• To prospectively compare pregnancy outcomes in individuals exposed to sumatriptan.
• To evaluate the risk of major birth defects following sumatriptan exposure during organogenesis.
• To compare outcomes against disease-matched and non-teratogen control groups.

Main Methods:

• Prospective cohort study design.
• Comparison of pregnancy outcomes including live births, spontaneous abortions, therapeutic abortions, and major birth defects.
• Inclusion of disease-matched and non-teratogen control groups for robust comparison.

Main Results:

• No statistically significant differences were observed in the rates of live births among the three groups.
• Rates of spontaneous abortions, therapeutic abortions, and major birth defects were similar across sumatriptan-exposed and control groups.
• This study provides the first prospective evidence on sumatriptan use during organogenesis.

Conclusions:

• Sumatriptan use during the first trimester (organogenesis) does not appear to be associated with an increased risk of major birth defects.
• Pregnancy outcomes following sumatriptan exposure are comparable to those in matched control populations.
• Further research may be warranted, but current findings suggest a favorable safety profile for sumatriptan in pregnancy.